Related Experiment Video
Updated: Feb 20, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
Chemical Profiling of Primary Mesothelioma Cultures Defines Subtypes with Different Expression Profiles and Clinical
Laurel M Schunselaar1, Josine M M F Quispel-Janssen2, Yongsoo Kim1
1Division of Oncogenomics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Abstract:
Purpose: Finding new treatment options for patients with malignant pleural mesothelioma is challenging due to the rarity and heterogeneity of this cancer type. The absence of druggable targets further complicates the development of new therapies. Current treatment options are therefore limited, and prognosis remains poor.Experimental Design: We performed drug screening on primary mesothelioma cultures to guide treatment decisions of corresponding patients that were progressive after first- or second-line treatment.Results: We observed a high concordance between in vitro results and clinical outcomes. We defined three subgroups responding differently to the anticancer drugs tested. In addition, gene expression profiling yielded distinct signatures that segregated the differently responding subgroups. These genes signatures involved various pathways, most prominently the fibroblast growth factor pathway.Conclusions: Our primary mesothelioma culture system has proved to be suitable to test novel drugs. Chemical profiling of primary mesothelioma cultures allows personalizing treatment for a group of patients with a rare tumor type where clinical trials are notoriously difficult. This personalized treatment strategy is expected to improve the poor prospects of patients with mesothelioma. Clin Cancer Res; 24(7); 1761-70. ©2017 AACRSee related commentary by John and Chia, p. 1513.
Insights
Drug screening of primary mesothelioma cultures accurately predicts patient response, enabling personalized treatment for malignant pleural mesothelioma. This approach offers hope for improving outcomes in this rare cancer.
Area of Science:
- Oncology
- Genomics
- Drug Discovery
Background:
- Malignant pleural mesothelioma is a rare and heterogeneous cancer with limited treatment options and poor prognosis.
- Developing new therapies is challenging due to the lack of druggable targets.
Purpose of the Study:
- To establish a drug screening platform using primary mesothelioma cultures to guide personalized treatment decisions.
- To identify patient subgroups and molecular signatures associated with differential drug responses.
Main Methods:
- Drug screening was performed on primary malignant pleural mesothelioma cultures from patients with progressive disease after standard treatments.
- Gene expression profiling was used to identify molecular signatures correlating with drug sensitivity.
- In vitro drug screening results were compared with clinical outcomes.
Main Results:
- High concordance was observed between in vitro drug screening results and patient clinical outcomes.
- Three distinct patient subgroups with differential responses to anticancer drugs were identified.
- Gene expression profiling revealed distinct molecular signatures, including those involving the fibroblast growth factor pathway, that segregated these subgroups.
Conclusions:
- Primary mesothelioma culture systems are effective for testing novel anticancer drugs.
- Chemical profiling of mesothelioma cultures enables personalized treatment strategies for this rare cancer.
- Personalized treatment based on drug screening is expected to improve outcomes for patients with malignant pleural mesothelioma.
